<p>Eli Lilly and Company (LLY), established in 1876, is a centennial global pharmaceutical powerhouse dedicated to developing and marketing medicines and vaccines across various therapeutic areas, including Alzheimer's disease, diabetes, oncology, metabolic disorders, and autoimmune diseases.</p>
<p>The company boasts a diversified product portfolio featuring market-leading drugs such as <strong>Trulicity</strong> (dulaglutide) for diabetes, <strong>Verzenio</strong> (abemaciclib) for breast cancer, and <strong>Taltz</strong> for psoriasis. However, its current growth is primarily driven by its blockbuster GLP-1 receptor agonists: <strong>Mounjaro</strong> (tirzepatide) and <strong>Zepbound</strong> (tirzepatide).</p>
<p>Lilly's current market valuation reflects strong investor confidence, largely due to its competitive advantage in the weight loss and type 2 diabetes markets. While the entry of competitors beyond Novo Nordisk poses a challenge to maintaining market share over the next three years, Lilly is aggressively expanding its pipeline beyond weight management.</p>

<h3>History and Key Milestones</h3>
<p>Eli Lilly was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Civil War veteran. After serving in the Union Army (1861–1865), he worked in several pharmacies before establishing his own manufacturing business.</p>

<h4>Early Development and Innovation (1876 – 1940s)</h4>
<ul>
    <li><strong>1876:</strong> Colonel Eli Lilly founded the company after a brief partnership with John F. Johnston. The initial focus was on high-quality drugs, including quinine for malaria.</li>
    <li><strong>1880s:</strong> Introduced innovations such as gelatin-coated pills/capsules and fruit-flavored or sugar-coated tablets for easier ingestion.</li>
    <li><strong>1923: Commercialization of Insulin.</strong> In collaboration with the University of Toronto, Lilly became the first company to mass-produce insulin (Iletin), establishing its leadership in diabetes care.</li>
    <li><strong>1940s:</strong> Pioneered the mass production of penicillin for Allied forces during World War II.</li>
</ul>

<h4>Post-War Expansion (1950s – 1980s)</h4>
<ul>
    <li><strong>1952:</strong> Became a publicly traded company.</li>
    <li><strong>1954:</strong> Entered animal health by establishing Elanco Products Company.</li>
    <li><strong>1955:</strong> Became one of the first manufacturers of the Salk polio vaccine.</li>
    <li><strong>1961:</strong> Developed its first oncology drug.</li>
    <li><strong>1971:</strong> Acquired Elizabeth Arden (cosmetics), later sold in 1987.</li>
    <li><strong>1977:</strong> Expanded into medical devices by acquiring IVAC and Cardiac Pacemakers.</li>
</ul>

<h4>Biotech Rise and Neuroscience Breakthroughs (1990s – Present)</h4>
<ul>
    <li><strong>1982:</strong> Launched <strong>Humulin®</strong> (human insulin), becoming one of the first companies to use recombinant DNA technology, cementing its diabetes leadership.</li>
    <li><strong>1986/1987:</strong> Launched <strong>Prozac®</strong> (fluoxetine). This selective serotonin reuptake inhibitor (SSRI) revolutionized depression treatment and established Lilly as a major player in neuroscience.</li>
</ul>

<h4>Modern Challenges and Transformation (2000s – Present)</h4>
<ul>
    <li><strong>2011:</strong> Formed an alliance with Boehringer Ingelheim to develop diabetes drugs, including Jardiance®.</li>
    <li><strong>2014:</strong> Acquired Novartis’ animal health business to strengthen Elanco (fully spun off in 2019).</li>
    <li><strong>2020:</strong> Rapidly developed monoclonal antibody therapies in response to the COVID-19 pandemic.</li>
    <li><strong>2022 – 2025:</strong> Executed a series of strategic acquisitions, including Akouos, DICE Therapeutics, Sigilon Therapeutics, Versanis Bio, Mablink Biosciences, POINT Biopharma, Morphic Therapeutic, and Scorpion Therapeutics.</li>
    <li><strong>2024:</strong> <strong>Kisunla™</strong> (donanemab) approved for early Alzheimer's disease; <strong>Ebglyss®</strong> (lebrikizumab) approved for atopic dermatitis.</li>
    <li><strong>2025:</strong> Continued focus on acquisitions and manufacturing capacity expansion.</li>
</ul>

<h3>Pharmaceutical Product Portfolio</h3>
<p>Eli Lilly maintains a robust pipeline addressing significant unmet medical needs.</p>

<h4>Top-Selling Products</h4>
<ul>
    <li><strong>Mounjaro (tirzepatide):</strong> Dual GLP-1/GIP receptor agonist for type 2 diabetes. Generated <strong>$11.54 billion</strong> in 2024. Projected to become the world's best-selling drug by 2030 ($36 billion).</li>
    <li><strong>Zepbound (tirzepatide):</strong> Indicated for weight management and Obstructive Sleep Apnea (OSA). Launched in late 2023, it rapidly accumulated <strong>$4.93 billion</strong> in 2024. Evaluate Pharma predicts sales of $25.5 billion by 2030.</li>
    <li><strong>Trulicity (dulaglutide):</strong> GLP-1 receptor agonist generating $7.1 billion in 2024. Patent expires in 2027.</li>
    <li><strong>Verzenio (abemaciclib):</strong> CDK4/6 inhibitor for breast cancer ($5.31 billion in 2024).</li>
    <li><strong>Jardiance (empagliflozin):</strong> SGLT2 inhibitor generating $3.34 billion in 2024 (+7.4% YoY).</li>
</ul>

<div class="image-container">
    <img src="assets/images/Eli Lilly Top-Selling Products.png" alt="Lilly 2024 Top-Selling Products">
    <p class="image-caption">Lilly's 2024 Top-Selling Products</p>
</div>

<h4>Recent Approvals</h4>
<ul>
    <li><strong>Kisunla™ (donanemab-azbt):</strong> Anti-amyloid beta mAb approved in July 2024 for Alzheimer's.</li>
    <li><strong>Tirzepatide (New Indication):</strong> Reduced heart failure outcomes by 38% in HFpEF patients with obesity (SUMMIT trial). Applications submitted to FDA/EMA.</li>
    <li><strong>Omvoh (mirikizumab):</strong> IL-23 antagonist for ulcerative colitis and Crohn’s disease.</li>
    <li><strong>EBGLYSS (lebrikizumab):</strong> IL-13 antagonist for atopic dermatitis.</li>
</ul>

<h4>Phase 3 Candidates with High Potential</h4>
<ul>
    <li><strong>Orforglipron:</strong> Oral GLP-1 receptor agonist. Phase 3 ACHIEVE-1 showed significant efficacy. Filing expected in 2026.</li>
    <li><strong>Remternetug:</strong> Next-generation anti-Aβ mAb for Alzheimer's.</li>
</ul>

<h4>Early-Stage Candidates</h4>
<ul>
    <li><strong>Lepodisiran:</strong> siRNA targeting <em>LPA</em>. Phase 2 data showed 94% reduction in Lp(a) with potential for infrequent dosing (up to 1.5 years).</li>
    <li><strong>Muvalaplin:</strong> Oral small molecule inhibiting Lp(a) formation. Phase 2 showed up to 85.8% reduction.</li>
</ul>

<h3>Patent Expirations (Loss of Exclusivity)</h3>
<ul>
    <li><strong>Trulicity (2027):</strong> Impact mitigated by Tirzepatide uptake.</li>
    <li><strong>Cyramza (2026):</strong> 2024 sales were $973.3 million.</li>
    <li><strong>Taltz:</strong> Biologics data protection expires in 2028; compound patent in 2030.</li>
</ul>
<p><small>Note: Biologics Data Protection (12 years in the US) prevents competitors from using the originator's data for biosimilar applications. Compound Patents (20 years) prevent the manufacture/sale of the specific molecule.</small></p>

<h3>Strategic Acquisitions and M&A</h3>
<p>Lilly utilizes a "string-of-pearls" strategy to access cutting-edge technologies.</p>
<h4>Key Acquisitions in First Half of 2025:</h4>
<ul>
    <li><strong>Scorpion Therapeutics (STX-478):</strong> Acquired for up to $2.5 billion. Mutant-selective PI3Kα inhibitor for breast cancer.</li>
    <li><strong>SiteOne Therapeutics (STC-004):</strong> Acquired for up to $1 billion. Non-opioid pain reliever targeting Nav1.8.</li>
    <li><strong>Verve Therapeutics (VERVE-102):</strong> Acquired for up to $1.3 billion. Base-editing gene therapy for ASCVD targeting PCSK9.</li>
</ul>

<h3>Financial Performance</h3>

<h4>2024 Full Year:</h4>
<ul>
    <li><strong>Revenue:</strong> $45.04 billion (+32% YoY).</li>
    <li><strong>Net Income:</strong> $10.59 billion (+102% YoY).</li>
    <li><strong>Gross Margin:</strong> 81.3%.</li>
</ul>

<h4>Q1 2025 Performance:</h4>
<ul>
    <li><strong>Global Revenue:</strong> $12.73 billion (+45% YoY).</li>
    <li><strong>Mounjaro:</strong> $3.84 billion (+112.7%).</li>
    <li><strong>Zepbound:</strong> $2.31 billion (+346.8%).</li>
</ul>

<div class="image-container">
    <img src="assets/images/Eli Lilly 2024 Revenue.png" alt="Lilly 2024 Revenue by Product">
    <p class="image-caption">Lilly's 2024 Revenue by Key Products</p>
</div>

<h3>Competitive Landscape</h3>
<h4>Obesity & Diabetes</h4>
<p><strong>Primary Competitor:</strong> Novo Nordisk (Semaglutide).<br>
Zepbound shows superior weight loss efficacy, but Novo has an oral semaglutide (Rybelsus) in Phase 3 for obesity.</p>

<h4>Oncology (PI3Kα Inhibitors)</h4>
<p><strong>Primary Competitor:</strong> Novartis (Alpelisib).<br>
Lilly's <strong>STX-478</strong> is mutant-selective and a monotherapy candidate, potentially avoiding metabolic toxicities associated with Alpelisib.</p>

<h4>Cholesterol / Lp(a)</h4>
<p>Lilly's <strong>Lepodisiran</strong> differentiates from Amgen and Silence Therapeutics via its long duration of action (up to 1.5 years). While the PCSK9 market is crowded, Lilly’s therapies address distinct risk factors.</p>

<h4>Atopic Dermatitis</h4>
<p><strong>EBGLYSS</strong> faces stiff competition from Sanofi's Dupixent, as well as oral JAK inhibitors (Cibinqo, Olumiant) and topical options (Opzelura).</p>

<h3>Summary</h3>
<p>Eli Lilly and Company remains a dominant force in the pharmaceutical industry, anchored by its historical leadership in diabetes and its current dominance with Mounjaro and Zepbound. With 2024 revenue growing 32% and net income doubling, the company is aggressively reinvesting in manufacturing and R&D.</p>
<p>Despite looming patent cliffs for legacy drugs like Trulicity, Lilly is successfully diversifying through strategic bolt-on acquisitions in oncology, gene editing, and immunology. The advancement of high-potential assets like the oral GLP-1 Orforglipron and the long-acting Lepodisiran positions Lilly to sustain its growth momentum and leadership in medical innovation for the coming decade.</p>
<br/>
